Tonix Pharmaceuticals Holding Corp. (TNXP)

Price$14.13

Favorite Metrics

Price vs S&P 500 (26W)-40.22%

Price vs S&P 500 (4W)-4.77%

Market Capitalization$187.47M

All Metrics

Book Value / Share (Quarterly)$19.17

P/TBV (Annual)0.82x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-8.07

Price vs S&P 500 (YTD)-10.84%

Gross Margin (TTM)49.34%

Net Profit Margin (TTM)-946.22%

EPS (TTM)$-14.25

10-Day Avg Trading Volume0.46M

EPS Excl Extra (TTM)$-14.25

EPS (Annual)$-14.57

ROI (Annual)-50.59%

Gross Margin (Annual)49.34%

Cash / Share (Quarterly)$16.24

Revenue Growth QoQ (YoY)108.75%

ROA (Last FY)-44.75%

Revenue Growth TTM (YoY)29.85%

EBITD / Share (TTM)$-14.77

ROE (5Y Avg)-69.94%

Operating Margin (TTM)-975.01%

Cash Flow / Share (Annual)$-8.07

P/B Ratio0.76x

P/B Ratio (Quarterly)0.81x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)-1.54x

Net Interest Coverage (TTM)-2.39x

ROA (TTM)-54.52%

EPS Incl Extra (Annual)$-14.57

Current Ratio (Annual)7.42x

Quick Ratio (Quarterly)6.99x

3-Month Avg Trading Volume0.45M

52-Week Price Return-11.21%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$19.16

P/S Ratio (Annual)14.30x

Asset Turnover (Annual)0.05x

52-Week High$69.97

EPS Excl Extra (Annual)$-14.57

CapEx CAGR (5Y)-17.01%

Tangible BV CAGR (5Y)91.96%

26-Week Price Return-36.24%

Quick Ratio (Annual)6.99x

13-Week Price Return-9.07%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.42x

Enterprise Value$-20.163

Asset Turnover (TTM)0.06x

Book Value / Share Growth (5Y)-26.22%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-946.22%

Cash / Share (Annual)$16.24

3-Month Return Std Dev76.32%

Net Income / Employee (TTM)$-1

ROE (Last FY)-50.59%

Net Interest Coverage (Annual)-421.14x

EPS Basic Excl Extra (Annual)$-14.57

Receivables Turnover (TTM)2.63x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-14.25

ROI (TTM)-60.15%

P/S Ratio (TTM)14.30x

Revenue / Share (Annual)$1.54

Tangible BV / Share (Annual)$19.16

Price vs S&P 500 (52W)-41.04%

Year-to-Date Return-8.19%

5-Day Price Return10.31%

EPS Normalized (Annual)$-14.57

ROA (5Y Avg)-57.45%

Net Profit Margin (Annual)-946.22%

Month-to-Date Return4.29%

Cash Flow / Share (TTM)$-10.41

EBITD / Share (Annual)$-14.82

Operating Margin (Annual)-975.01%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-67.27%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-14.25

P/TBV (Quarterly)0.82x

P/B Ratio (Annual)0.81x

Inventory Turnover (TTM)0.92x

Pretax Margin (TTM)-946.22%

Book Value / Share (Annual)$19.17

Price vs S&P 500 (13W)-9.76%

Beta1.82x

Revenue / Share (TTM)$1.11

ROE (TTM)-60.15%

52-Week Low$11.60

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.13

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
TNXPTonix Pharmaceuticals Holding Corp.	14.30x	29.85%	49.34%	—	$14.13
LLYEli Lilly & Co.	13.08x	44.70%	83.04%	27.59%	$903.99
JNJJohnson & Johnson	5.94x	7.87%	67.95%	14.90%	$234.54
ABBVABBVIE INC.	6.04x	8.57%	71.62%	-2.88%	$208.99
MRKMerck & Co., Inc.	4.41x	1.31%	78.55%	21.23%	$115.46
AZNAstraZeneca PLC	5.28x	8.63%	81.31%	21.88%	$200.47
NVSNovartis AG	4.98x	8.91%	75.82%	15.26%	$149.73
NVONovo-Nordisk A/S	3.62x	6.43%	80.98%	20.66%	$40.93
ABTAbbott Laboratories	3.66x	6.59%	56.50%	8.20%	$95.47
PFEPfizer Inc.	2.47x	-1.64%	75.81%	-3.51%	$27.22
BMYBristol-Myers Squibb Co.	2.47x	-0.22%	72.63%	—	$58.96

About

Tonix Pharmaceuticals is a commercial-stage biotech company developing treatments for CNS disorders and immunological conditions. Its approved product TONMYA treats fibromyalgia, while marketed migraine medications Zembrace SymTouch and Tosymra provide current revenue. The company is expanding TONMYA into depression and acute stress disorder through clinical trials and advancing a pipeline including TNX-4800 for Lyme disease prevention and TNX-1500 for transplant rejection prevention.